Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article contrasts Recursion Pharmaceuticals’ AI-driven, multi-partner drug discovery platform with Summit Therapeutics’ single-asset bet on ivonescimab in lung cancer. Recursion reported FY2025 revenue of ~$74.7M (+26.9% YoY) but a net loss of ~$644.8M and negative free cash flow of ~$378.3M, while Summit recorded no revenue, a larger FY2025 net loss of ~$1.1B, and negative free cash flow of ~$240.2M. Financial risk appears mixed—Recursion shows low leverage (debt-to-equity ~0.1x; current ratio ~5.5x) versus Summit’s no-debt stance (debt-to-equity ~0; current ratio ~9.9x) but higher clinical concentration risk due to reliance on ivonescimab. Overall, the piece implies a slight portfolio-tilt toward Recursion for diversification, though both remain capital-intensive and uncertain until trial/regulatory outcomes.

Analysis

This is mostly a debate about which risk the market is underpricing: platform duration or binary concentration. RXRX can keep its valuation elevated only if partnership revenue is increasingly seen as a proving ground for owned assets; otherwise, the market will eventually haircut the AI narrative into expensive R&D services. The upside case is not near-term revenue but a credible path to serial pipeline conversion over the next 6-18 months.

SMMT is the opposite: it can re-rate far faster, but only on a narrow set of readouts, and any disappointment is likely to be discontinuous rather than gradual. The second-order winner from a miss is not just MRK/BMY sentiment relief; it is also a repricing of how much capital the market is willing to allocate to single-asset oncology stories with large partner obligations. If the drug works, the bigger issue becomes whether the economics are good enough to justify the commercial dilution, not just the biology.

Contrarian take: the market may be too willing to reward diversification when the diversified revenue stream is still too small to matter, and too dismissive of a concentrated asset when the time-to-inflection is short. RXRX is the cleaner long only if management can show that partner activity is converting into proprietary clinical evidence; otherwise the multiple is vulnerable to compression on every risk-off biotech tape. SMMT is a better event trade than an investment thesis, with the main falsifier being a clean efficacy/safety package that changes standard-of-care math in lung cancer.

Key Decisions for Investors

• Initiate a long RXRX / short SMMT pair trade on a 3-6 month horizon; size for event risk, not fundamentals. The spread should work if the market continues to reward de-risking and punish binary concentration. Falsify the trade if SMMT posts clearly superior data or if RXRX loses a meaningful partner relationship.
• If taking single-name exposure, prefer RXRX only on pullbacks after biotech risk-off days; the cleaner catalyst is 6-18 months of partner-to-pipeline conversion, not next quarter revenue. Target is multiple stability plus incremental upside as the platform proves it can generate owned assets.
• Avoid naked short SMMT unless you can tolerate gap risk. If you want bearish exposure, use put spreads around known clinical/regulatory windows so the premium paid is capped if the market gets surprised by a positive readout.
• Watch MRK and BMY as indirect hedges: if ivonescimab disappoints, the incumbent oncology basket should retain pricing power and sentiment support. If SMMT wins, expect the read-through to be more about combination-therapy pressure than immediate franchise disruption.